Inspire Investing LLC Has $407,000 Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Inspire Investing LLC lifted its position in shares of Biohaven Ltd. (NYSE:BHVN) by 32.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,895 shares of the company’s stock after purchasing an additional 2,698 shares during the quarter. Inspire Investing LLC’s holdings in Biohaven were worth $407,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ARS Investment Partners LLC lifted its holdings in Biohaven by 1.0% during the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock worth $38,871,000 after acquiring an additional 10,473 shares in the last quarter. Weybosset Research & Management LLC raised its position in shares of Biohaven by 23.9% during the fourth quarter. Weybosset Research & Management LLC now owns 13,645 shares of the company’s stock worth $510,000 after purchasing an additional 2,635 shares during the period. Diversified Trust Co lifted its holdings in shares of Biohaven by 16.6% during the 4th quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock valued at $209,000 after purchasing an additional 795 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Biohaven by 85.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock valued at $40,448,000 after purchasing an additional 372,737 shares during the period. Finally, Franklin Resources Inc. increased its stake in Biohaven by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock worth $4,206,000 after purchasing an additional 412 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insiders Place Their Bets

In other Biohaven news, Director John W. Childs purchased 29,000 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the transaction, the director now owns 2,368,741 shares in the company, valued at $85,132,551.54. The trade was a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 16.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price (up previously from $58.00) on shares of Biohaven in a report on Wednesday, December 4th. JPMorgan Chase & Co. boosted their price target on Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd. TD Cowen lifted their target price on Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $59.00 price target on shares of Biohaven in a research report on Tuesday, December 17th. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $63.00.

Biohaven Stock Performance

Shares of BHVN opened at $39.36 on Friday. The firm’s 50-day simple moving average is $40.37 and its 200 day simple moving average is $42.49. The firm has a market cap of $3.98 billion, a P/E ratio of -4.21 and a beta of 1.29. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21.

Biohaven (NYSE:BHVN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, equities analysts forecast that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.